PubMed HealthSearch

PubMed · 6604203

Splenic imaging.

Abstract

Before the advent of ultrasonography and computed tomography the spleen was an organ generally neglected by the radiologist. Today, there are five possible ways of splenic imaging: (1) plain radiography, (2) ultrasonography, (3) spleen scintigraphy, (4) computed tomography, and (5) splenic arteriography. The potentials and limitations of these different imaging modalities are discussed. Based upon a recent retrospective analysis of 194 cases with focal splenic lesions, an algorithmic pathway is suggested, where real-time ultrasonography is used as the first imaging method. In equivocal or negative results it is followed by CT which is the most accurate and best reproducible method. Nuclear medicine offers several important non-imaging function tests (e.g. red cell and platelet survival) but splenic scintigraphy is of minor importance except for the detection of aberrant spleens and splenic tissue. Selective splenic arteriography is rarely necessary for diagnostic purposes except the study of portal circulation but may become valuable again for transcatheter embolization ("medical splenectomy").

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P E Peters, R Lorenz, M Fischer. 1983. Splenic imaging.. https://pubmed.ncbi.nlm.nih.gov/6604203/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Local treatment with antithrombotic drugs can prevent thrombus formation: an angioscopic and angiographic study.

OBJECTIVES: This study was designed to evaluate the efficacy of local versus systemic treatment of thrombosis with various antithrombotic drugs. BACKGROUND: Local use of low dose antithrombotic drugs has been proposed as being effective and safe. METHODS: Heparin (30 U/kg), an antithrombin agent (argatroban, 0.05 mg/kg body weight) or a defibrinogenating drug (batroxobin, 0.05 U/kg) was locally infused into one side of the canine iliac artery after injury by balloon inflation. The other side was injured as a control. The efficacy of systemic delivery of high dose (heparin [300 U/kg] and argatroban [0.5 mg/kg]) and low dose drugs was also assessed. RESULTS: Sixty minutes after local treatment in 22 dogs, no thrombotic stenosis was observed by angiography in locally treated arteries (p < 0.005 vs. mean thrombotic stenosis of 27% in control segments for heparin, 25.3% in control segments for argatroban and 32% in control segments for batroxobin). Angioscopy demonstrated the same trend. In locally treated arteries, thrombus weight was significantly lower in the treated than control side. In the systemic high dose group (n = 10), angiographic thrombotic stenosis was < 5% after high dose drug delivery (p < 0.05 vs. control segments, 37.4% for heparin, 43% for argatroban). In another 10 dogs, low dose systemic delivery was not effective in inhibiting thrombus formation. Activated partial thromboplastin time and fibrinogen levels did not change with local treatment. CONCLUSIONS: Compared with systemic administration of antithrombotic drugs, local treatment is a safer and more effective method of preventing thrombosis.

Angiography

Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.

BACKGROUND: Recent studies have suggested that vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) may have synergistic effects on the induction of angiogenesis in vitro. Therefore, we investigated the hypothesis that the simultaneous administration of VEGF and bFGF, each having been previously shown to independently enhance collateral development in an animal model of hind limb ischemia, could have a synergistic effect in vivo. METHODS AND RESULTS: Ten days after surgical induction of unilateral hind limb ischemia, New Zealand White rabbits were randomized to receive either VEGF 500 micrograms alone (n = 6), bFGF 10 micrograms alone (n = 7), VEGF 500 micrograms, immediately followed by 10 micrograms bFGF (n = 7), or vehicle only (control animals, n = 8) in each case administered intra-arterially via a catheter in the internal iliac artery of the ischemic limb. BP ratio (BPR, ischemic/healthy limb) at day 10 for the VEGF+bFGF group was 0.82 +/- 0.01, much superior (P < .0005) to that of either the VEGF group (0.52 +/- 0.02) or the bFGF group (0.57 +/- 0.02). This outcome persisted at day 30: BPR in the VEGF+bFGF group (0.91 +/- 0.02) exceeded that of the control group (0.49 +/- 0.05, P < .0001), the VEGF group (0.65 +/- 0.03, P < .0005), or the bFGF group (0.66 +/- 0.03, P < .0005). Serial angiography demonstrated a progressive increase in luminal diameter of the stem collateral artery and the number of opacified collaterals in the thigh of the ischemic limbs in all groups. Stem artery diameter with VEGF+bFGF (1.34 +/- 0.07 mm) on day 30 was significantly (P < .05) greater than with either VEGF (1.09 +/- 0.09) or bFGF (1.18 +/- 0.06) alone. Capillary density was significantly greater (P < .05) in VEGF+bFGF animals (275 +/- 20 mm2) compared with VEGF (201 +/- 8) or bFGF (209 +/- 15). CONCLUSIONS: Combined administration of VEGF and bFGF stimulates significantly greater and more rapid augmentation of collateral circulation, resulting in superior hemodynamic improvement compared with either VEGF or bFGF alone. This synergism of two angiogenic mitogens with different target cell specificities may have important implications for the treatment of severe arterial insufficiency in patients whose disease is not amenable to direct revascularization.

Angiography

[Treatment of symptomatic carotid stenosis].

Published results and experience at the University Hospital of Zurich clearly indicate that in patients with severe, symptomatic carotid artery stenosis the benefits of carotid endarterectomy clearly outweigh the risks. Surgical treatment also favorably influences outcome in cases with contralateral carotid artery occlusion.

Angiography